Nat Med. 2004 Sep;10(9):887-92.

Cancer immunotherapy: breaking the barriers to harvest the crop.

Source

Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. dmpardol@jhmi.edu

Abstract

Successful translation of modern molecular immunology into effective cancer immunotherapy is threatened by regulatory barriers and challenges to the development of novel agents and combinatorial strategies through effective public-private partnerships. For its promise to be fully realized, both the National Cancer Institute and Food and Drug Administration must take active steps to help academic investigators and companies jointly navigate the pathways from laboratory to clinic.

Comment in

PMID:: 15340404; [PubMed - indexed for MEDLINE]

MeSH Terms, Substances

MeSH Terms

Substances

Drug Combinations

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical

Cancer - MedlinePlus Health Information

Supplemental Content

Save items

Related citations in PubMed

Translation of cancer immunotherapies. [Nat Med. 2004]
Translation of cancer immunotherapies.
Mulé JJ, Weber JS. Nat Med. 2004 Nov; 10(11):1153; author reply 1153-4.
Translation of cancer immunotherapies. [Nat Med. 2004]
Translation of cancer immunotherapies.
Skipper J, Hoffman EW, O'Donnell-Tormey J, Old LJ. Nat Med. 2004 Nov; 10(11):1154-5; author reply 1155.
Business barriers slowing the pace of cancer immunotherapy research and development. [J Natl Cancer Inst. 2007]
Business barriers slowing the pace of cancer immunotherapy research and development.
Tuma RS. J Natl Cancer Inst. 2007 Nov 7; 99(21):1570-3. Epub 2007 Oct 30.
Review The academic surgeon and industry. [J Thorac Cardiovasc Surg. 2000]
Review The academic surgeon and industry.
Kaiser LR. J Thorac Cardiovasc Surg. 2000 Apr; 119(4 Pt 2):S29-32.
Review The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute. [Stem Cells. 1996]
Review The clinical development of paclitaxel: a successful collaboration of academia, industry and the National Cancer Institute.
Donehower RC. Stem Cells. 1996 Jan; 14(1):25-8.

See reviews... See all...

Cited by 9 PubMed Central articles

The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells. [Ann N Y Acad Sci. 2009]
The human cancer antigen mesothelin is more efficiently presented to the mouse immune system when targeted to the DEC-205/CD205 receptor on dendritic cells.
Wang B, Kuroiwa JM, He LZ, Charalambous A, Keler T, Steinman RM. Ann N Y Acad Sci. 2009 Sep; 1174:6-17.
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. [Cancer Res. 2009]
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model.
Wada S, Yoshimura K, Hipkiss EL, Harris TJ, Yen HR, Goldberg MV, Grosso JF, Getnet D, Demarzo AM, Netto GJ, et al. Cancer Res. 2009 May 15; 69(10):4309-18. Epub 2009 May 12.
Review Dendritic cells: a critical player in cancer therapy? [J Immunother. 2008]
Review Dendritic cells: a critical player in cancer therapy?
Palucka AK, Ueno H, Fay J, Banchereau J. J Immunother. 2008 Nov-Dec; 31(9):793-805.

See all...

Related information

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Recent activity

Clear Turn Off Turn On

Cancer immunotherapy: breaking the barriers to harvest the crop.
Cancer immunotherapy: breaking the barriers to harvest the crop.
Nat Med. 2004 Sep ;10(9):887-92.

PubMed
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian...
Evaluation of psychosocial effects of pre-symptomatic testing for breast/ovarian and colon cancer pre-disposing genes: a 12-month follow-up.
Fam Cancer. 2004 ;3(2):109-16.

PubMed
HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological simila...
HNPCC and sporadic MSI-H colorectal cancer: a review of the morphological similarities and differences.
Fam Cancer. 2004 ;3(2):93-100.

PubMed
Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified prot...
Exploring the O-GlcNAc proteome: direct identification of O-GlcNAc-modified proteins from the brain.
Proc Natl Acad Sci U S A. 2004 Sep 7 ;101(36):13132-7. Epub 2004 Aug 30 .

PubMed
Innate immune responses in peptidoglycan recognition protein L-deficient mice.
Innate immune responses in peptidoglycan recognition protein L-deficient mice.
Mol Cell Biol. 2004 Sep ;24(18):7949-57.

PubMed

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

PubMed

Result Filters

Display Settings:

Send to: